It's marketed as a generic option to name-brand mood meds, but it's been recalled for the same reason a competitor was just ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Genetic testing is transforming depression treatment by tailoring antidepressants to your DNA for better results and fewer side effects.

A new study has found that adults with depression who start treatment with newer antipsychotic medications may face a higher ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

Sooma announced that it received FDA investigational device exemption (IDE) for its transcranial direct current stimulation ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

This summary highlights key global health developments, including J&J halting studies of a depression drug due to low ...